Literature DB >> 7904438

Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus.

S Hori1, Y Ohshita, Y Utsui, K Hiramatsu.   

Abstract

The acquisition of ofloxacin resistance by a susceptible clinical Staphylococcus aureus strain was found to be achieved in two sequential steps: the first step was accompanied by 4-fold increases in the ofloxacin MIC and 8- to 16-fold increases in the norfloxacin MIC. The second step was accompanied by further increases in both the ofloxacin and the norfloxacin MICs. A mutation of the gyrA gene resulting in an amino acid substitution was found in the second-step but not in the first-step resistant subclone. On the other hand, there was no difference in the accumulation of norfloxacin in the parent strain and the resistant subclones of each step. The rates of mutation to resistance in the steps were (1.58 to 6.81) x 10(-9) and (0.71 to 2.59) x 10(-9), respectively, and did not depend on whether the parent strain was resistant to methicillin. Some implications of these observations for clinical as well as mechanistic aspects of the prevalence of methicillin- and ofloxacin-resistant S. aureus are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7904438      PMCID: PMC192379          DOI: 10.1128/AAC.37.11.2278

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Active efflux mechanisms for antimicrobial resistance.

Authors:  S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  H M Blumberg; D Rimland; D J Carroll; P Terry; I K Wachsmuth
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

3.  A Factor (or Mutator Gene) Influencing Mutation Rates in Escherichia Coli.

Authors:  H P Treffers; V Spinelli; N O Belser
Journal:  Proc Natl Acad Sci U S A       Date:  1954-11       Impact factor: 11.205

4.  DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.

Authors:  S Sreedharan; M Oram; B Jensen; L R Peterson; L M Fisher
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

5.  The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein.

Authors:  A A Neyfakh
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

6.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Authors:  M Trucksis; J S Wolfson; D C Hooper
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

Review 8.  Impermeability to quinolones in gram-positive and gram-negative bacteria.

Authors:  L E Bryan; J Bedard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

9.  Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

Authors:  W Cullmann; M Stieglitz; B Baars; W Opferkuch
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

10.  Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins.

Authors:  E E Margerrison; R Hopewell; L M Fisher
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490

View more
  26 in total

1.  Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.

Authors:  M Takei; H Fukuda; R Kishii; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.

Authors:  Masaya Takei; Hideyuki Fukuda; Ryuta Kishii; Youko Kadowaki; Yukiko Atobe; Masaki Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

3.  Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus.

Authors:  T Niga; H Yoshida; H Hattori; S Nakamura; H Ito
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Genetic and Transcriptomic Analyses of Ciprofloxacin-Tolerant Staphylococcus aureus Isolated by the Replica Plating Tolerance Isolation System (REPTIS).

Authors:  Miki Matsuo; Miyu Hiramatsu; Madhuri Singh; Takashi Sasaki; Tomomi Hishinuma; Norio Yamamoto; Yuh Morimoto; Teruo Kirikae; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

5.  Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.

Authors:  F J Schmitz; M E Jones; B Hofmann; B Hansen; S Scheuring; M Lückefahr; A Fluit; J Verhoef; U Hadding; H P Heinz; K Köhrer
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

7.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors:  J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.